Another big pharma player is making a move in the cannabis and botanical medicines space. This time around, it’s NYSE-traded, a manufacturer of over-the-counter health and wellness products valued at more than $7 billion.a company focused on the production of AI-powered, medical-grade vaporization devices – for cannabis and other botanical medicines.
In fact, current research suggests it can take up to 30 attempts for a person to quit smoking,. “However, a strong smoking cessation program yields success rates as high as 40%,” he added. “Perrigo is committed to help smokers who want to kick the habit through our diverse portfolio of cessation products and solutions designed to meet each individual's needs.”James Dillard
“Given the current controversies regarding ENDS [Electronic Nicotine Delivery System] products, we believe there is an opportunity for consumers to have access to an ENDS system that is safe and effective and has been approved by appropriate regulatory authorities,” Dillard explains in a press release that will hit the wire later today. “Perrigo is the right company to work with regulatory bodies like the FDA given our unique portfolio of NRT products.
Zedd